Press Releases June 4, 2026 04:09 PM

SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026

SI-BONE to present at 2026 Truist Securities MedTech Conference, highlighting advancements in procedural solutions for compromised bone.

By Jordan Park SIBN

SI-BONE, a Nasdaq-listed company specializing in procedural solutions for compromised bone, announced its participation in the 2026 Truist Securities MedTech Conference. The company will host a fireside chat focusing on their technology platform that targets spinopelvic anatomy and innovations addressing clinical challenges related to low-density bone in the sacrum. SI-BONE has supported over 150,000 procedures and maintains a strong clinical evidence base.

SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SIBN

Key Points

  • SI-BONE will present at the prestigious Truist Securities MedTech Conference on June 16, 2026.
  • The company specializes in procedural solutions targeting compromised bone, particularly in the spinopelvic area.
  • SI-BONE’s technologies are supported by extensive clinical evidence including randomized controlled trials and peer-reviewed publications.

SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/b4rPMsFmx6FA94q8B8jb82. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 185 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Saqib Iqbal: [email protected]


Risks

  • Dependence on continued clinical success and adoption of their procedural solutions in a specialized medical segment.
  • Potential competitive advancements in the MedTech sector addressing similar bone-related conditions.
  • Market and regulatory uncertainties impacting medical device companies could affect future growth and product deployment.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026